Objective: To study the efficacy and safety of low-dose oral tetrahydrocannabinol (THC) in the treatment of dementia-related neuropsychiatric symptoms (NPS).
studies suggested improvement in agitation and nocturnal motor activity in patients with Alzheimer disease (AD). 12, 13 The effect of THC on the endocannabinoid system is mediated by 2 cannabinoid receptors: CB 1 receptors are expressed in several brain regions, especially the basal ganglia, cerebellum, hippocampus, amygdala, and hypothalamus; CB 2 receptors are primarily found in cells and organs of the immune system. Therefore, THC probably has a wide range of CB 1 -mediated receptor interactions with the endocannabinoid system affecting emotion, cognition, and behavior. Moreover, psychotropic effects are also exerted through interaction with other receptors and neurotransmitters, such as acetylcholine, dopamine, serotonin, g-aminobutyric acid, glutamate, norepinephrine, prostaglandins, and opioid peptides. 14 Interestingly, several animal studies also suggest a neuroprotective effect of cannabinoids in the disease pathology of AD itself, which is primarily based on a reduction in the inflammatory response by microglia cells and the increase of amyloid-b clearance. 15, 16 Nonetheless, firm evidence of the efficacy and safety of THC or other cannabinoids in this vulnerable patient group is lacking and data on older patients in general are scarce. 17 The current article reports the largest study carried out so far on evaluating the efficacy and safety of oral THC for behavioral disturbances in patients with dementia.
METHODS Standard protocol approvals, registrations, and patient consents. This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice, approved by a certified ethics committee of the Radboud university medical center (Radboudumc) and registered at www.clinicaltrials.org (NCT01608217). Assessments were done by researchers from the Department of Geriatric Medicine of Radboudumc (Nijmegen, the Netherlands) and the Department of Elderly of Vincent van Gogh Institute (psychiatric hospital, Venray, the Netherlands) from November 2012 to June 2014. Participants were recruited from 9 participating institutes throughout the southeast of the Netherlands, including geriatric outpatient clinics (n 5 2 clinics), psychiatric clinics (n 5 3), nursing homes (n 5 3, including in total 6 locations), and a regional network of integrated care for community-dwelling patients with dementia. Written informed consent was provided at screening by the patient and closest involved proxy, the first only in case the patient was judged capable of consent. Study design. This was a randomized, double-blind, placebocontrolled, multicenter, phase II trial. Potential participants were screened for eligibility within 4 weeks prior to start of study medication, by assessment of somatic and cognitive status and severity of behavioral disturbances. Assessments were done at the outpatient clinic, nursing home, or at home, depending on patient preference. Study intervention was initiated after baseline. Efficacy assessments were scheduled after 14 6 2 treatment days (phone call) and 21 6 2 treatment days (visit). For the purpose of safety assessment and compliance, several phone calls were performed by the researchers during the intervention period (days 2, 7, and 14). Follow-up assessments by telephone were performed 2 weeks after study completion.
Participants. Patients diagnosed with AD or vascular or mixed dementia according to National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association 18 or National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche en l'Enseignement en Neurosciences 19 criteria were eligible for participation if they had clinically relevant NPS (minimal Neuropsychiatric Inventory [NPI] score $10), with symptoms reported on agitation, aggression, or aberrant motor behavior, existing at least 1 month prior to screening. A caregiver had to be available who was in touch with the patient at least twice a week and supervised the patient's care. Exclusion criteria were current major psychiatric disorders and any severe or instable concomitant illness, in particular seizures, arrhythmias necessitating treatment other than a b-blocker or digoxin, severe heart failure, or any concomitant disease necessitating treatment changes. Other exclusion criteria were frequent falling due to orthostatic hypotension, a history or current alcohol or drug abuse, and use of tricyclic antidepressants, fluoxetine, or carbamazepine. Use of concurrent psychotropic medication was allowed, provided that the dose and frequency were kept stable within 2 weeks before and during trial conduction. Analgesic drugs had to be stopped prior to baseline assessments, although use of analgesic and psychotropic escape medication was allowed.
Changes to study protocol. We initially recruited patients with behavioral disturbances as well as persistent pain complaints to secondarily assess the efficacy of THC on pain in patients with dementia. However, the number of eligible patients with both symptoms was much lower than predicted from the literature. 20 After inclusion of the first 8 patients, the criterion of pain was omitted. In the amended study, pain assessments were still included, allowing secondary evaluation of the efficacy of THC in reducing pain-related behavior and pain intensity in a subgroup of patients, of which the methods and results are described in appendix e-1 and table e-1 on the Neurology ® Web site at Neurology.org.
Intervention and randomization. Active treatment consisted of 1.5 mg THC in tablet form (Namisol, Echo Pharmaceuticals, Weesp, the Netherlands) 3 times daily for a period of 3 weeks. This daily dose was based on preliminary positive results of previous trials in patients with severe AD. 12, 13, 21 Control treatment consisted of matched placebo tablets. Additionally, patients received 1,000 mg acetaminophen 3 times daily in case of pain complaints, or of suspected pain in noncommunicative patients, based on physical examination at screening and information from the caregiver or physician. Study medication was administered at 9 AM, 2 PM, and 8 PM by the primary caregiver or nursing home staff. Study medication was packed and distributed by the pharmacy of Radboudumc according to Good Manufacturing Practice. Randomization (allocation ratio 1:1) was performed by an independent statistician using a computer-generated randomization program, of which the algorithm was stratified per center and minimized 22 for NPI score, dementia severity, sex, and current opioid use. Treatment allocation was strictly concealed from participants, caregivers, investigators, and all other personnel directly involved in the study and was not made available until study completion and database lock.
Outcome measures. Primary outcome measure. The primary outcome was change in NPS, measured with NPI. 23 This questionnaire evaluates 12 behavioral domains, including agitation/ aggression and aberrant motor behavior, which were the behavioral domains of interest. The frequency and severity of NPS were scored per domain by questioning a caregiver, which resulted in a total score ranging from 0 to 144 (a higher score indicating greater impairment). NPI was assessed at baseline, day 14 (by telephone interview), and day 21 by trained researchers.
Secondary efficacy outcome measures. Secondary outcomes included assessment of agitated behavior and aggression (Cohen-Mansfield Agitation Inventory [CMAI] 24 ), activities of daily living (Barthel Index 25 ), and quality of life (Quality of Life-Alzheimer's Disease Scale [QoL-AD] 26 ). These were all assessed at baseline and day 21. Overall change was assessed by the primary caregiver, using the Caregiver Clinical Global Impression of Change (CCGIC), a 7-point scale ranging from marked improvement to marked worsening from baseline.
Safety assessments. Adverse events. Adverse events (AEs) were solicited from patients and their caregivers at all visits and phone calls up to 2 weeks after study drug discontinuation, using clinical observation, open questions, and a set of questions on possible THC-related adverse symptoms, including the most frequently reported AEs in the phase I study with healthy elderly. 27 AEs were coded following the classification of Medical Dictionary for Regulatory Activities. An AE was defined as serious if it was fatal or life-threatening, required or prolonged hospitalization, or resulted in persistent or significant disability or incapacity.
Other safety assessments. Other safety assessments consisted of evaluation of blood pressure, heart rate, and weight, assessed at screening, baseline, and day 21, and ECG and biochemistry and hematology blood samples, assessed at screening and day 21. The Paired Associate Learning Wechsler Memory Scale-Revised (PAL WMS-R) 28 was used for assessment of possible effects of THC on episodic memory function (baseline and day 21).
Statistical analysis. The study sample size was estimated based on a clinically relevant difference of 4 points on NPI, 29,30 a SD of 12 points, 31, 32 and an estimated correlation with baseline of 0.6 and interclass correlation coefficient of 0.6. Approximately 130 patients were required for a power of 80% (2-sided testing at 0.05). We were not able to enroll this number of subjects within the available time period, due to delay in getting formal approval for THC use at all sites from the Health Care Inspectorate. After trial ending, we performed an analysis to calculate the power to yield a statistically significant difference in favor of THC, in case we would have been able to extend the study to 130 subjects. This analysis is known as the calculation of conditional power. The analysis used 10,000 simulated extensions of the outcome data of the realized sample to the planned sample size, based on the real data that were acquired. Efficacy and safety analyses were based on the intention-to-treat principle and performed in accordance with a prespecified statistical analysis plan, finalized before unmasking of treatment assignment. RESULTS Study participants. In total, 54 patients were assessed for eligibility, of whom 50 were randomized and received study medication (THC, n 5 24; placebo, n 5 26) ( figure) . Patient characteristics are presented in table 1. Overall, 47 patients (94%) completed the study, while 3 patients discontinued participation due to the occurrence of AEs (n 5 2) and withdrawal of informed consent (n 5 1).
Treatment compliance and concurrent medication use.
Median treatment compliance, based on remaining pill count, was 98% (67%-100%) in the THC group and 100% (94%-100%) in the placebo group. Twenty-nine patients received acetaminophen (THC, n 5 13; placebo, n 5 16). Four patients (16.7%) in the THC group received escape medication, compared to 2 patients (7.7%, p 5 0.33) in the placebo group, which consisted of benzodiazepines (oxazepam 5 mg, lorazepam 1 mg) and acetaminophen (500 mg). . Two patients dropped out due to the occurrence of AEs; one patient developed pneumonia within 2 days after initiation of THC treatment, and one patient experienced persistent nausea on placebo. One serious AE occurred during placebo treatment, which was not related to study medication. This patient was admitted to a specialized dementia care unit due to high caregiver burden.
Other safety outcomes. There were no changes between the groups concerning heart rate, blood pressure, and weight (table 2). Episodic memory scores were available for 18 patients with a mild dementia severity. PAL WMS-R scores decreased by 1.2 points in the THC group and 1.4 points in the placebo group, which was not significantly different (p 5 1.0). DISCUSSION We found no benefit of 4.5 mg oral THC daily on behavioral disturbances in patients with dementia after 3 weeks of treatment. Additionally, there were no benefits for THC on quality of life, activities of daily living, or pain-related behavior and pain intensity (appendix e-1), while THC was safe and well-tolerated. The number of patients experiencing AEs was similar in both groups, while known THC-mediated AEs, such as dizziness, somnolence, and falls, were more frequently reported during placebo treatment. None of the participants reported a feeling "high," nor was behaving "high" observed by caregivers or research staff. The current trial is the largest randomized controlled trial (RCT) so far studying oral THC in NPS in dementia, with valid and rigorous trial methods. The study sample was representative for the overall dementia population, in terms of age, dementia severity, and domestic situation. Patients with severe aggressive behavior could not be included, as the study's safety assessments cannot be adequately conducted in this group. Taking into account this limitation associated with this specific patient population, we have included a sample that is representative for the majority of the target population with clinically relevant NPS; the level of behavioral disturbances, assessed by NPI, was moderate and comparable to previous intervention trials. [33] [34] [35] We observed an improvement in NPS in both groups over the duration of the study period, which has been reported before. 34, 35 The substantial degree of improvement in the placebo group is striking (table 2), and may be due to many factors including attention and support by the study team, expectations of patients and caregivers concerning THC, and training of nursing home Table 2 Overview of study results of the application of THC on neuropsychiatric symptoms in dementia personnel (together called the Hawthorne or instudy effect 36 ). To correct for this substantial placebo response within individual patients, it might be worthwhile to implement an individually randomized crossover design in future studies. Despite the fact that we studied a vulnerable patient population, the attrition level was low (6%) and adherence high (98%-100%). This suggests a highly motivated group of participants and caregivers, in combination with the occurrence of only mild AEs. This study has some limitations. Most importantly, we failed to enroll the planned number of patients, despite comprehensive recruitment efforts throughout various health care settings. Rigorous national regulations on medical cannabinoids hindered implementation of the study in the participating clinics. Additionally, fewer than expected patients visiting the clinics had clinically relevant NPS as well as pain.
Omitting the latter inclusion criterion significantly stimulated the recruitment. Despite this underenrollment, the conditional power of 5% emphasizes that it was very unlikely that exposure of more participants to the study interventions and assessments would have influenced our conclusion. Contrary to the current RCT, previous studies all reported positive effects of oral THC (2.5-7 mg daily) in patients with dementia. 12, 13, 21, 37 However, important methodologic factors significantly limit the robustness of these findings: inclusion of small number of patients (n 5 2 and n 5 15) and uncontrolled or retrospective study designs. In a previous randomized trial, we studied dosages up to 3 mg THC daily, and did not observe a significant reduction in NPS, nor any relevant AEs or effects on vital functions or mobility (unpublished data, 2014). Therefore, we used a dosage of 4.5 mg THC daily in this study. Recent developments regarding the extended legalization of marijuana for medical purposes in over 30 US states has stimulated the discussion of the therapeutic potential and safety profile of cannabinoids for various indications. 38, 39 Momentarily, effective and safe treatments for NPS in patients with dementia are lacking. 40 Several pharmacotherapeutic options have been explored, such as acetylcholinesterase inhibitors and antidepressants, 33, 34 but they often have a suboptimal benefit-risk profile. For example, while high-dose citalopram appears to effectively reduce agitation and overall behavioral disturbances, significant cardiac AEs limit its usefulness in this vulnerable population. 34 Our current trial indicates that 4.5 mg THC daily can be safely administered to patients with dementia. The observation that there was no biological signal of AEs suggests that the dosage was too low, as a psychoactive drug is rarely effective without showing any side Table 3 Patients experiencing adverse events Aspartate aminotransferase increased 0 (0.0) 2 (7.7)
Blood alkaline phosphatase increased 0 (0. MedDRA system organ class and preferred term THC (n 5 24) Placebo (n 5 26)
Neck pain 1 (4.2) 0 (0.0)
Pain in extremity 1 (4.2) 0 (0.0)
Eye disorders 0 (0.0) 2 (7.7)
Dry eyes 0 (0.0) 1 (3.8)
Eye hemorrhage 0 (0.0) 1 (3.8)
Renal and urinary disorders 0 (0.0) 2 (7.7)
Renal impairment 0 (0.0) 1 (3.8)
Urge incontinence 0 (0.0) 1 (3.8) 
Skin disorders

